Armistice Capital’s Virax Biolabs VRAX Stock Holding History

Armistice Capital’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,152	Closed	-$193K	–	416
2026 Q1	$193K	Buy	+35,152	New	+$216K	﹤0.01%	229
2024 Q1	–	Sell	-4,880	Closed	-$178K	–	415
2023 Q4	$178K	Buy	+4,880	New	+$285K	﹤0.01%	243
2023 Q2	–	Sell	-6,000	Closed	-$1.04M	–	269
2023 Q1	$1.04M	Buy	+6,000	New	+$1.17M	0.02%	139

Other funds holding VRAX

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's VRAX Position: Q2 2026 in Review

Armistice Capital sold out of Virax Biolabs (VRAX) in Q2 2026, closing a stake of 35,152 shares — an estimated $193K sold.

Armistice Capital first reported a position in VRAX in Q1 2023 and held it in 3 quarters. The position peaked at $1.04M in Q1 2023. 2 funds tracked by Wall St. Rank hold VRAX as of Q2 2026.

Armistice Capital reported no remaining Virax Biolabs position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 35,152 Virax Biolabs shares in Q2 2026, an estimated $193K.
Armistice Capital first reported a position in Virax Biolabs in Q1 2023 and held it in 3 quarters.
Armistice Capital's Virax Biolabs position peaked at $1.04M in Q1 2023.
2 funds tracked by Wall St. Rank held Virax Biolabs as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.